concept

ALZHEIMER'S DISEASE PROGRESSION

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about ALZHEIMER'S DISEASE PROGRESSION: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

33Connections

0Hypotheses

8Analyses

0Outgoing

33Incoming

0Experiments

9Debates

No summary available yet.

View on Wiki →

No AI portrait yet

💡 Concept Info

Name	ALZHEIMER'S DISEASE PROGRESSION

Pathway Diagram

graph TD
    ALZHEIMER_S_DISEASE_PROGRESSIO["ALZHEIMER'S DISEASE PROGRESSION"]
    TET2_Mutant_Myeloid_Cells["TET2-Mutant Myeloid Cells"] -->|"inhibits"| ALZHEIMER_S_DISEASE_PROGRESSIO
    Enhanced_Phagocytosis["Enhanced Phagocytosis"] -->|"inhibits"| ALZHEIMER_S_DISEASE_PROGRESSIO
    Cerebrospinal_Fluid_Biomarkers["Cerebrospinal Fluid Biomarkers"] -.biomarker for.-> ALZHEIMER_S_DISEASE_PROGRESSIO
    Metabolic_Dysfunction["Metabolic Dysfunction"] -->|"contributes to"| ALZHEIMER_S_DISEASE_PROGRESSIO
    Gut_Brain_Axis["Gut-Brain Axis"] -->|"modulates"| ALZHEIMER_S_DISEASE_PROGRESSIO
    CNS_Infiltration["CNS Infiltration"] -->|"mediates"| ALZHEIMER_S_DISEASE_PROGRESSIO
    Cortical_Astrocytes["Cortical Astrocytes"] -->|"modulates"| ALZHEIMER_S_DISEASE_PROGRESSIO

Outgoing (0)

Target	Relation	Type	Str
No outgoing edges

Incoming (33)

Source	Relation	Type	Str
TET2-Mutant Myeloid Cells	inhibits	cell_type	0.95
Gut-Brain Axis	modulates	pathway	0.90
Enhanced Phagocytosis	inhibits	process	0.90
39402379	characterized by	paper	0.90
Anti-amyloid therapies	targets	drug	0.90
Cerebrospinal Fluid Biomarkers	biomarker_for	biomarker	0.90
Metabolic Dysfunction	contributes_to	disease	0.90
CNS Infiltration	mediates	process	0.88
Gut-Brain Axis	modulates	pathway	0.88
Cortical Astrocytes	modulates	cell_type	0.87
Plasma GFAP	risk_factor_for	biomarker	0.87
YKL-40	risk_factor_for	protein	0.85
CNS Infiltration	modulates	process	0.85
Neuromelanin Loss	contributes_to	phenotype	0.85
APOE4	risk_factor_for	gene	0.85
Disease-Associated Microglia	modulates	cell_type	0.85
Phagocytosis	involved_in	process	0.85
Blood-Brain Barrier Function Preservation	protects_against	process	0.85
Gut Microbiota Alterations	contributes_to	biomarker	0.85
AMYLOID BETA	associated_with	protein	0.85
Gut Microbiota Dysbiosis	biomarker_for	biomarker	0.82
NREM Sleep Reduction	contributes_to	phenotype	0.80
DAM Activation	modulates	process	0.80
DAM Activation	inhibits	process	0.80
Amyloid beta clearance	modulates	process	0.75
anti-amyloid monotherapy	modulates	drug	0.70
inflammatory cytokines	associates_with	process	0.70
synaptic gene downregulation	associated_with	phenotype	0.70
neurofilament light chain	biomarker_for	biomarker	0.70
Aβ	initiates	protein	0.70
microglial lipid handling dysfunction	associated_with	process	0.70
TREM2 dysregulation	associated_with	process	0.70
microglial activation states	regulates	phenotype	0.70

Targeting Hypotheses (0)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
No targeting hypotheses

Mentioning Analyses (8)

Scientific analyses that reference this entity

Non-Neuronal Transcriptional Changes Preceding Tau Propagation as Early AD Bioma

neurodegeneration | 2026-04-27 | 3 hypotheses Top: 0.626

Epigenetic clocks as biomarkers for Alzheimer disease and neurodegeneration

neurodegeneration | 2026-04-25 | 6 hypotheses Top: 0.387

scRNA-seq Processing and Cell Type Annotation of AD Brain

neurodegeneration | 2026-04-16 | 1 hypotheses Top: 0.618

Why have anti-Aβ clinical trials failed despite the established role of Aβ in AD

neurodegeneration | 2026-04-16 | 2 hypotheses Top: 0.741

Are interneuron oscillation deficits compensatory responses or primary pathologi

neurodegeneration | 2026-04-15 | 1 hypotheses Top: 0.747

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (9)

Multi-agent debates referencing this entity

Which non-neuronal cell types (astrocytes, oligodendrocytes, pericytes) exhibit

closed · Rounds: 4 · Score: 0.67 · 2026-04-28

Epigenetic clocks as biomarkers for Alzheimer disease and neurodegeneration

completed · Rounds: 5 · Score: 0.50 · 2026-04-25

Which cell types show the greatest vulnerability in Alzheimer's disease accordin

closed · Rounds: 4 · Score: 0.75 · 2026-04-22

While SPP1 absence prevents synaptic loss, it's unclear whether this represents

closed · Rounds: 4 · Score: 0.69 · 2026-04-21

Can standardized scRNA-seq processing and automated annotation identify novel ce

closed · Rounds: 4 · Score: 0.70 · 2026-04-21

Does the hybrid DAM + interferon-response microglial population represent a nove

closed · Rounds: 4 · Score: 0.70 · 2026-04-16

The abstract suggests that Aβ-tau synergy could explain negative results from an

closed · Rounds: 4 · Score: 0.65 · 2026-04-16

The debate raised whether SST/PV interneuron dysfunction represents adaptive com

closed · Rounds: 4 · Score: 0.76 · 2026-04-16

Why have numerous phase 3 clinical trials failed despite advances in understandi

closed · Rounds: 5 · Score: 0.67 · 2026-04-12

Related Research

Hypotheses and analyses mentioning ALZHEIMER'S DISEASE PROGRESSION in their description or question text

No additional research found

ALZHEIMER'S DISEASE PROGRESSION

Understanding Entity Pages

Pathway Diagram

Outgoing (0)

Incoming (33)

Targeting Hypotheses (0)

Mentioning Analyses (8)

Non-Neuronal Transcriptional Changes Preceding Tau Propagation as Early AD Bioma

Epigenetic clocks as biomarkers for Alzheimer disease and neurodegeneration

scRNA-seq Processing and Cell Type Annotation of AD Brain

Why have anti-Aβ clinical trials failed despite the established role of Aβ in AD

Are interneuron oscillation deficits compensatory responses or primary pathologi

Why have numerous phase 3 clinical trials failed despite advances in understandi

Does SPP1-mediated synaptic engulfment represent beneficial clearance or patholo

Cell type vulnerability debate in Alzheimer's disease (SEA-AD v4)

Experiments (0)

Related Papers (0)

Debates (9)

Which non-neuronal cell types (astrocytes, oligodendrocytes, pericytes) exhibit

Epigenetic clocks as biomarkers for Alzheimer disease and neurodegeneration

Which cell types show the greatest vulnerability in Alzheimer's disease accordin

While SPP1 absence prevents synaptic loss, it's unclear whether this represents

Can standardized scRNA-seq processing and automated annotation identify novel ce

Does the hybrid DAM + interferon-response microglial population represent a nove

The abstract suggests that Aβ-tau synergy could explain negative results from an

The debate raised whether SST/PV interneuron dysfunction represents adaptive com

Why have numerous phase 3 clinical trials failed despite advances in understandi

Related Research